Newron Valuation Report "Down but not out!" update

Wednesday, May 5, 2021 @ 12:00 am

After digesting the setback of sarizotan in Rett syndrome, Newron is close to start two pivotal evenamide trials in schizophrenia and the Xadago pivotal trial in PD-LID, unlocking substantial equity upside. Newron is trading well below the value of its approved drug Xadago with no value contributed to its pipeline.

Key catalysts include:

1. Results evenamide “Study 008A” (end 2021)
2. Start pivotal trials evenamide in schizophrenia/CTRS (Q1 2022)
3. Start new label trial Xadago in PD-LID (Q1 2022)

Read full Newron Valuation Report "Down but not out!"

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Vandria becoming clinical stage company: First clinical trial for neurodegenerative disorders

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announces that the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout of this combined single and multiple ascending dose trial is expected in the summer of 2025.
December 18, 2024

BioCopy's CEO Matthias Wiedenfels among Germany's biotech pioneers of the coming decade

BioCopy CEO Matthias Wiedenfels honored as winner of "Germany's 30 by 2030" award.
December 17, 2024

The co-founders of AlphaMol are ranked as the "top 2% scientists" in the world

December 16, 2024

Porton Pharma Solutions: Collaboration with Aojin Life Sciences in China and USA

December 13, 2024

MedScienceSwiss: Combatting antibiotic-resistant bacteria with “Plan B”

MedScienceSwiss is developing a non-pharmaceutical therapy for the treatment of antibiotic-resistant bacteria. The goal: to significantly reduce the number of deaths in hospitals due to nosocomial (difficult-to-treat) infections. The technology is not only intended to serve as an alternative to the current plan A (antibiotics), but also to function as a general approach to the treatment of resista
December 3, 2024